For Healthcare Professionals Outside the US
Employ broad biomarker testing to identify patients with an actionable mutation3
ESMO, European Society for Medical Oncology; NCCN, National Comprehensive Cancer Network.
References: 1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.1.2018. © National Comprehensive Cancer Network, Inc. 2018. www.nccn.org. Accessed January 9, 2018. 2. Besse B, Adjei A, Baas P, et al; and Panel Members. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475-1484. 3. Lovly C, Horn L, Pao W. Molecular profiling of lung cancer. My Cancer Genome website. https://www.mycancergenome.org/content/disease/lung-cancer/. Updated March 28, 2016. Accessed March 13, 2017. 4. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non–small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574-3579. 5. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19(16):4532-4540. 6. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046-2051. 7. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.